Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The effectiveness of grass, birch, and mugwort pollen allergen immunotherapy over 18 years: A national cohort study in Denmark

Peter Bager, Gry Poulsen, Jan Wohlfahrt, Mads Melbye
doi: https://doi.org/10.1101/2022.11.16.22282380
Peter Bager
1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pbg{at}ssi.dk
Gry Poulsen
1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
2Aalborg University, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Wohlfahrt
1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mads Melbye
2Aalborg University, Copenhagen, Denmark
3Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
4Danish Cancer Society Research Center, Copenhagen, Denmark
5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
6K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Long-term effectiveness of pollen allergen immune therapy (AIT) for allergic rhinitis (AR) has been studied for different durations. We studied effectiveness over 18 years using nationwide register-data for Denmark.

Methods A register-based cohort study using data on filled prescriptions, 1995-2018, Denmark. In a cohort of 1.1 million intranasal corticosteroid spray users (proxy for AR), we matched users treated with grass, birch or mugwort (GBM) AIT 1:2 with non-treated users on baseline year and 24 characteristics in the 3 years prior to baseline. The primary outcome was the odds ratio (OR) of using anti-allergic nasal spray during the pollen season in the treated vs. non-treated group modelled in a logistic generalized estimating equations analysis using an autoregressive correlation structure and adjusted for years since baseline (one year categories).

Results Among 7,914 AR patients treated with GBM AIT, the OR of using nasal spray 0-5 years after baseline was reduced when compared with 15,520 non-treated AR individuals (0-2 years, odds ratio (OR) 0.81(0.76-0.85); 3-5 years, OR 0.82(0.77-0.87)), but was close to unity or higher thereafter (6-9 years, OR 0.96(0.91-1.03); 10-18 years, OR 1.15(1.06-1.24). In post-hoc analyses, results were more consistent for those who already had 3 of 3 baseline years of use (0-2 years, OR 0.59 (0.54-0.64); 3-5 years, OR 0.64 (0.59-0.71); 6-9 years, 0.82 (0.75-0.91); 10-18 years, 0.95 (0.84-1.08), and in patients using nasal spray in the last pollen season (0-2 years, OR 0.76 (0.72-0.80); 3-5 years 0.84 (0.78-0.91); 6-9 years, OR 0.94 (0.86-1.03); 10-18 years, 0.90 (0.81-1.00)) as opposed to patients who did not use nasal spray in the last pollen season. The post-hoc findings were likewise more consistent for eye drop and oral antihistamine users (secondary outcomes).

Conclusion Patients treated with GBM AIT in routine care to a higher degree stopped using anti-allergic nasal spray 0-5 years after starting the standard three years of therapy. Post-hoc analyses suggested results were more consistent among patients with persistent AR.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by grants from Aase og Ejnar Danielsens Fond (19-10-0208), Dagmar Marshalls Fond, Fonden til Lægevidenskabens Fremme (A.P. Møller og Hustru Chastine McKinney Møller 18-L-0194), Hartmann Fonden (A33348), and Helsefonden (16-B0320). Dr Bager was supported by a grant from Oak Foundation (OCAY-12-319). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Danish Data Protection Agency (no. 15/09765). According to Danish law, ethics approval is exempt for such research. Due to the nature of this research, there was no involvement of patients or members of the public in the design or reporting of this study. Direct dissemination to study participants is not possible. Permission from the Danish Health and Medicines Authority has been granted (no. 15/09765).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Not Applicable

Footnotes

  • Data availability statement: The data are available for research upon reasonable request to the Danish Health and Medicines Authority, Statistics Denmark, and the Research services for the Danish Health Data authority within the framework of the Danish data protection legislation and any required permission from relevant authorities.

  • Source of Funding: This study was supported by grants from Aase og Ejnar Danielsens Fond (19-10-0208), Dagmar Marshalls Fond, Fonden til Lægevidenskabens Fremme (A.P. Møller og Hustru Chastine McKinney Møller; 18-L-0194), Hartmann Fonden (A33348), and Helsefonden (16-B0320). Dr Bager was supported by a grant from Oak Foundation (OCAY-12-319). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability

The data are available for research upon reasonable request to the Danish Health and Medicines Authority, Statistics Denmark, and the Research services for the Danish Health Data authority within the framework of the Danish data protection legislation and any required permission from relevant authorities.

  • Abbreviations

    AIT
    allergen immunotherapy;
    AR
    allergic rhinitis;
    GBM
    grass-birch-mugwort;
    NS
    nasal spray;
    INS
    intranasal corticosteroid spray;
    GP
    general practitioner.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted November 18, 2022.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    The effectiveness of grass, birch, and mugwort pollen allergen immunotherapy over 18 years: A national cohort study in Denmark
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    The effectiveness of grass, birch, and mugwort pollen allergen immunotherapy over 18 years: A national cohort study in Denmark
    Peter Bager, Gry Poulsen, Jan Wohlfahrt, Mads Melbye
    medRxiv 2022.11.16.22282380; doi: https://doi.org/10.1101/2022.11.16.22282380
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    The effectiveness of grass, birch, and mugwort pollen allergen immunotherapy over 18 years: A national cohort study in Denmark
    Peter Bager, Gry Poulsen, Jan Wohlfahrt, Mads Melbye
    medRxiv 2022.11.16.22282380; doi: https://doi.org/10.1101/2022.11.16.22282380

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Epidemiology
    Subject Areas
    All Articles
    • Addiction Medicine (430)
    • Allergy and Immunology (757)
    • Anesthesia (221)
    • Cardiovascular Medicine (3298)
    • Dentistry and Oral Medicine (365)
    • Dermatology (280)
    • Emergency Medicine (479)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
    • Epidemiology (13384)
    • Forensic Medicine (19)
    • Gastroenterology (899)
    • Genetic and Genomic Medicine (5157)
    • Geriatric Medicine (482)
    • Health Economics (783)
    • Health Informatics (3275)
    • Health Policy (1143)
    • Health Systems and Quality Improvement (1193)
    • Hematology (432)
    • HIV/AIDS (1019)
    • Infectious Diseases (except HIV/AIDS) (14636)
    • Intensive Care and Critical Care Medicine (913)
    • Medical Education (478)
    • Medical Ethics (127)
    • Nephrology (525)
    • Neurology (4930)
    • Nursing (262)
    • Nutrition (730)
    • Obstetrics and Gynecology (886)
    • Occupational and Environmental Health (795)
    • Oncology (2524)
    • Ophthalmology (728)
    • Orthopedics (282)
    • Otolaryngology (347)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (544)
    • Pediatrics (1302)
    • Pharmacology and Therapeutics (551)
    • Primary Care Research (557)
    • Psychiatry and Clinical Psychology (4218)
    • Public and Global Health (7512)
    • Radiology and Imaging (1708)
    • Rehabilitation Medicine and Physical Therapy (1016)
    • Respiratory Medicine (980)
    • Rheumatology (480)
    • Sexual and Reproductive Health (498)
    • Sports Medicine (424)
    • Surgery (549)
    • Toxicology (72)
    • Transplantation (236)
    • Urology (205)